Abstract
The aim of our study was to review the clinicopathologic features and management of atypical chronic myeloid leukemia (aCML). Relevant manuscripts published in English were searched using PubMed. aCML is diagnosed as per WHO 2016 classification in the presence of leukocytosis ≥13 × 109/l with circulating neutrophil precursors ≥10%, monocytes less than 10%, minimal basophils, hypercellular bone marrow with granulocytic proliferation and dysplasia, bone marrow blast less than 20% and absence of BCR/ABL fusion gene. Common cytogenetic features and mutations include trisomy 8, and mutations in SETBP1 and ETNK1. Median survival is 1-2 years. Hematopoietic stem cell transplant may be the only curative option. Ruxolitinib and dasatinib are emerging therapeutic options. Thus, aCML is a rare entity with poor survival. Novel therapies are needed.
Original language | English (US) |
---|---|
Pages (from-to) | 177-185 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 14 |
Issue number | 2 |
DOIs | |
State | Published - Jan 2018 |
Keywords
- actionable mutation
- atypical chronic myeloid leukemia
- decitabine
- hematopoietic stem cell transplant
- targeted therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research